our Premium Content: News alerts, weekly reports and conference planners

GENE:

ETV6 (ETS Variant Transcription Factor 6)

News alerts, weekly reports and conference planners

Primary Indolent Acute Promyelocytic Leukemia. (PubMed, Hematol Rep)

Induction therapy with all-trans-retinoic acid and arsenic trioxide resulted in hematologic remission...Atypical clinical trajectories should prompt careful assessment of marrow morphology and immunophenotypic features. Continued characterization of such cases may refine diagnostic criteria and direct individualized approaches to therapy.

3 days ago

Journal

TP53 (Tumor protein P53) • ETV6 (ETS Variant Transcription Factor 6)

TP53 mutation • Chr t(15;17)

arsenic trioxide

Interplay between genetic ancestry, self-reported race and ethnicity, and clinical factors in pediatric acute lymphoblastic leukemia: A REDIAL Consortium Report. (PubMed, Cancer Epidemiol Biomarkers Prev)

This analysis offers insights into factors underlying disparities in ALL outcomes and may be targeted to mitigate them, ultimately guiding more equitable approaches to risk stratification and intervention.

7 days ago

Journal

RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2)

FBXW7 mutations reprogram glucose metabolism by activating the ETV6-GLUT1 axis. (PubMed, Mol Cancer)

Importantly, targeting GLUT1 pharmacologically partially reverses the proliferative advantage conferred by ETV6 overexpression, highlighting a promising therapeutic vulnerability. Our findings establish the FBXW7-ETV6-GLUT1 regulatory axis as a critical driver of metabolic adaptation and tumor progression, offering potential strategies for targeted therapy in FBXW7-mutant EC.

9 days ago

Journal

ETV6 (ETS Variant Transcription Factor 6) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • SLC2A1 (Solute Carrier Family 2 Member 1)

Pediatric NTRK-rearranged gliomas: A clinicopathological and molecular analysis of six cases. (PubMed, Pathol Res Pract)

This study expands the clinicopathological and molecular spectrum of pediatric NTRK-rearranged gliomas, including rare entities and complex fusion patterns, and supports routine NTRK testing in pediatric gliomas irrespective of histological grade.

9 days ago

Journal

TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ETV6 (ETS Variant Transcription Factor 6) • MSH2 (MutS Homolog 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CHEK1 (Checkpoint kinase 1) • NTRK (Neurotrophic receptor tyrosine kinase) • ARHGEF11 (Rho Guanine Nucleotide Exchange Factor 11)

NTRK fusion

17d

LEAH: Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals (clinicaltrials.gov)

P=N/A, N=5909, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Initiation date: Jun 2025 --> Feb 2026

17 days ago

Trial initiation date

TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • POLE (DNA Polymerase Epsilon) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • RAD51D (RAD51 paralog D) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • DICER1 (Dicer 1 Ribonuclease III) • FLCN (Folliculin) • PRSS1 (Serine Protease 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TXNIP (Thioredoxin Interacting Protein) • ANKRD26 (Ankyrin Repeat Domain Containing 26) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • HOXB13 (Homeobox B13)

TP53 mutation • PTEN deletion

20d

Genomic characterization and prognostic significance of copy number alterations in Tunisian patients with acute lymphoblastic leukemia. (PubMed, PLoS One)

Additionally, the integration of IKZF1 deletion status into risk stratification models revealed markedly different survival outcomes, highlighting its potential interest in developing new stratification algorithms. These results underscore the critical importance of molecular profiling, particularly IKZF1 status, for improving outcomes in ALL patients in Tunisia.

20 days ago

Journal

ABL1 (ABL proto-oncogene 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ETV6 (ETS Variant Transcription Factor 6) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5)

CDKN2A deletion

20d

ETS Variant Transcription Factor 6 Promotes Glucose Metabolism Reprogramming in HCC. (PubMed, J Cell Mol Med)

Mechanistically, ETV6 binds to the miR-429 promoter, mediating glucose metabolic reprogramming in HCC cells by targeting CRKL via the PI3K/AKT pathway. Taken together, these findings reveal that the ETV6-miR-429-CRKL regulatory circuitry plays a crucial role in glucose metabolic reprogramming in HCC, offering novel insight and a potential target for cancer therapy.

20 days ago

Journal

ETV6 (ETS Variant Transcription Factor 6) • CRKL (CRK Like Proto-Oncogene, Adaptor Protein) • MIR429 (MicroRNA 429) • TFAM (Transcription Factor A, Mitochondrial)

24d

Describing the Mutational Characteristics of Myxofibrosarcoma: An AACR Project GENIE Analysis. (PubMed, Anticancer Res)

As we enter the era of precision medicine, classifying cancers by molecular markers will become increasingly valuable. Our investigation enriches the literature by identifying novel mutations and mutations exclusive to certain demographic groups. These findings support a shift beyond histology toward molecularly informed diagnostics and pathway-directed therapeutic hypotheses for MFS. Next steps should validate candidate markers in independent cohorts and link genomic profiles to clinicopathologic features, disease course, and treatment response to improve clinical translation. These observations will help shape diagnostics and targeted therapies against MFS.

24 days ago

Journal

TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • ETV6 (ETS Variant Transcription Factor 6) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler) • NOTCH3 (Notch Receptor 3) • NCOR1 (Nuclear Receptor Corepressor 1) • FLCN (Folliculin) • ALOX12B (Arachidonate 12-Lipoxygenase) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • NCOA2 (Nuclear Receptor Coactivator 2) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)

TP53 mutation • CDKN2A deletion

27d

Metastatic and recurrent salivary gland carcinoma: clinical characteristics and comprehensive molecular profiling at a tertiary care center. (PubMed, J Cancer Res Clin Oncol)

The impact of immunohistochemical or molecular markers on treatment selection and response was most pronounced in SDC. HER2 IHC2 + expression was observed across multiple subtypes, indicating that TDxd may represent a potential treatment option for more pts than previously anticipated. The impact of comprehensive genomic profiling on targeted treatment options is currently still modest.

27 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)

HER-2 amplification • HER-2 expression

Vitrakvi (larotrectinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)

28d

Prolonged survival in EGFR exon 20 insertion mutant lung adenocarcinoma: case report of sequential osimertinib and furmonertinib with research trend analysis. (PubMed, Front Med (Lausanne))

This analysis demonstrated a growing global research focus on third-generation EGFR-TKIs and variant-specific treatment strategies for EGFR ex20ins-mutant NSCLC, supporting the rationale underpinning the therapeutic approach adopted in this report. Sequential high-dose third-generation EGFR-TKIs may offer clinically meaningful benefit in selected EGFR ex20ins cases; however, this strategy remains non-standard and should be regarded as hypothesis-generating, warranting further prospective evaluation.

28 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • ETV6 (ETS Variant Transcription Factor 6) • SMAD4 (SMAD family member 4) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)

PD-L1 expression • TP53 mutation • EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation

Tagrisso (osimertinib) • Ivesa (firmonertinib) • simmitinib (SYHA1817)

The GF-NEO discovery platform unveils a [KQE][DG] sequence motif within fusion neoantigens in pediatric cancer. (PubMed, iScience)

Finally, a multipronged validation strategy using in vitro and in vivo systems confirms the GF-NEOs presentation through mass spectrometry-based proteomics and immunopeptidomics. Multiple GF-NEOs encoded by two versions of the ETV6-RUNX1 fusion were validated, paving the way for targeted immunotherapy development.

1 month ago

Journal

RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6)